Loading...
MIT Sloan Health Systems Initiative (HSI) - Lunch Series: AI Agents: Accelerants for Drug Discovery and Commercialization
E62-450
100 Main Street, Cambridge, MA United States
153
Registered
Registration
Registration is now closed (this event already took place).
Details
AI Agents: Accelerants for drug Discovery & Commercialization
Wednesday November 12
Location: E62-450
Time: 11:30am - 1pm
Lunch will be provided in person.
Zoom link
Password: 1015
This session will explore how AI agents are impacting the pharmaceutical landscape from initial drug discovery to successful commercialization. Attendees will gain insights into the practical applications of these intelligent systems and their potential to overcome long-standing challenges in bringing novel therapies to patients faster.
Harison Hong is a physician-executive with over 10 years of biopharma leadership experience across global and US commercial strategy and drug launches. He has led multiple successful launches, including Dupixent ($14Bn) and Nemluvio, and currently serves as Executive Director, Brand Lead for navenibart at Astria Therapeutics. A board-certified physician and 2014 Sloan MBA graduate, he is particularly interested in how AI is transforming drug commercialization and accelerating patient access. He is also passionate about traveling and soccer and he lives with his wife and son in Newton.
Tim Sun has 10+ years of experience at Google bringing AI technologies to market. He currently works on the Cloud Go-to-Market team, partnering with leading Biotech companies on using AI to accelerate drug discovery and commercialization. Tim graduated from Sloan with an MBA in 2014. He lives in Cambridge with his wife and two kids.
Food Provided (Email Lisa Maloney lmaloney@mit.edu with any dietary concerns.)
Speakers
Tim Sun, MBA
Cloud AI Go-to-Market
https://www.linkedin.com/in/timsun1/
Tim has 10+ years of experience at Google bringing AI technologies to market. He currently works on the Cloud Go-to-Market team, partnering with leading Biotech companies on using AI to accelerate drug discovery and commercialization. Tim graduated from Sloan with an MBA in 2014. He lives in Cambridge with his wife and two kids.
Harison Hong, MD, MBA
Executive Director, Brand Lead - navenibart
Astria Therapeutics, Inc.
https://www.linkedin.com/in/harison-c-hong/
Harison Hong is a physician-executive with over 10 years of biopharma leadership experience across global and US commercial strategy and drug launches. He has led multiple successful launches, including Dupixent ($14Bn) and Nemluvio, and currently serves as Executive Director, Brand Lead for navenibart at Astria Therapeutics. A board-certified physician and 2014 Sloan MBA graduate, he is particularly interested in how AI is transforming drug commercialization and accelerating patient access. He is also passionate about traveling and soccer and he lives with his wife and son in Newton.
"Ana" Anne Quaadgras
Director
MIT Sloan Health Systems Initiative
https://www.linkedin.com/in/anne-quaadgras-6208778/
Is the Director of the MIT Sloan Health Systems Initiative and a Senior Lecturer at MIT Sloan.
Her work focuses on health systems transformation, and the role of information technology in supporting that change.
Prior to her doctoral work, Anne was a management consultant for fifteen years, specializing in improving decision-making and investment processes in the chemical, pharmaceutical, and financial services industries.
She holds a Bachelor’s and Master’s degree in chemical engineering from MIT. Anne earned her doctorate in information systems at Boston University, where her dissertation research explored how globally distributed groups of experts recognize and respond to operational problems.
Hosted By
Co-hosted with: Healthcare Club, Health Systems Initiative (OWNER)
Contact the organizers